bullish
Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market
650 Views16 Jul 2018 13:36
Ascletis Pharma, a China-based biotechnology company, is raising up to USD 300 million to listing on the Hong Kong Stock Exchange. Ascletis is the...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)23 Jul 2018
- Ascletis Pharma (1672 HK) IPO: First in Line23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)23 Jul 2018
- Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)14 Sep 2017
- Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)13 Sep 2017
x